SMT + PE-A 5%
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute-On-Chronic Liver Failure
Conditions
Acute-On-Chronic Liver Failure
Trial Timeline
Feb 21, 2019 → Apr 14, 2025
NCT ID
NCT03702920About SMT + PE-A 5%
SMT + PE-A 5% is a phase 3 stage product being developed by Grifols for Acute-On-Chronic Liver Failure. The current trial status is terminated. This product is registered under clinical trial identifier NCT03702920. Target conditions include Acute-On-Chronic Liver Failure.
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03702920 | Phase 3 | Terminated |
Competing Products
2 competing products in Acute-On-Chronic Liver Failure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VS-01 on top of SOC | Genfit | Phase 2 | 17 |
| Single Dose G1090N + Multiple dosing of G1090N | Genfit | Phase 1 | 19 |